Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beijing Univ. of Chemical Technology L858R/T790M/C797S mutant EGFR compound L15: sourced facts only. name: "Compound L15 demonstrated potent inhibitory activity against the L858R/T790M/C797S mutant EGFR (IC50 = 16.43 nM), exhibiting 5-fold selectivity over wild-type EGFR (IC50 = 80.96 nM)."; target: "Compound L15 demonstrated potent inhibitory activity against the L858R/T790M/C797S mutant EGFR (IC50 = 16.43 nM), exhibiting 5-fold selectivity over wild-type EGFR (IC50 = 80.96 nM)."; developer: "State Key Laboratory of Chemical Resource Engineering, Department of Pharmaceutical Engineering, Beijing University of Chemical Technology, P.O. Box 53, 15 BeiSanHuan East Road, Beijing 100029, P. R. China."
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Beijing Univ. of Chemical Technology L858R/T790M/C797S mutant EGFR compound L15.
Work on Beijing Univ. of Chemical Technology L858R/T790M/C797S mutant EGFR compound L15? Claim this page to correct or add information. Claim this page